Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Iressa Response Working, Company Says: Docs Move To Tarceva

Executive Summary

AstraZeneca's efforts to promote Genentech/OSI's Tarceva as the first-choice epidermal growth factor receptor therapy are working, the company told FDA's Oncologic Drugs Advisory Committee March 4

You may also be interested in...



Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”

As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005

Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”

As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005

Zarnestra Phase III Trial May Lack Sufficient Power To Show Survival Benefit

An ongoing Phase III trial of Johnson & Johnson's acute myeloid leukemia therapy Zarnestra may lack sufficient power to show a survival benefit, the FDA Oncologic Drugs Advisory Committee biostatistician suggested May 6

Related Content

Topics

UsernamePublicRestriction

Register

PS045490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel